Amgen Inc to Acquire Worldwide Rights to Otezla® from Celgene Corp - Conference Call Transcript
My name is Laura, and I will be your conference facilitator today for Amgen's conference call on the acquisition of Otezla. (Operator Instructions)
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.
Okay, Laura, thank you. Good morning, everybody, and thanks for joining us on short notice.
Our announced acquisition of Otezla this morning is an important step in adding to our leadership
in the inflammation space. To address this in greater detail, I'm joined with -- joined by several members of our leadership team this morning.
And just a reminder that some of the statements we make today will be forward-looking statements and our SEC filings identify factors that could cause our actual results to differ materially.
So with that, I would like to turn the call over to Bob Bradway, our CEO. Bob?
Okay, Arvind. Thank
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |